Operating Loss of 4.3B Won, EGM Called for Charter Amendment and Director Pay Cap

FY2025 consolidated revenue fell 10.6% YoY to ₩73.7B; operating loss of ₩4.3B (swing to red); net loss of ₩7.7B.
39th EGM convenes on June 25, 2026; agenda: partial amendment of articles of incorporation and approval of director remuneration limit.
Charter amendment: change 'outside director' to 'independent director'; adjust liability cap for independent directors to 3x annual salary (same as before); reflect revised Commercial Act.
Director remuneration limit proposal: approve total cap of ₩1.1B for 3 directors (1 independent) – previous limit rejected at last AGM; actual remuneration paid in prior year was ₩790M.
Q1 2026 related-party transaction with Coreana Bio: ₩6.5B (34.9% of consolidated revenue).
Outside director Park Dong-jin attended 100% of board meetings and voted in favor of all resolutions.

ADVERTISEMENT (250px+)